Shares of RTI Surgical (RTIX) are poised for a gap up at the open. Investors appear to like the prospects of two new products launched today.
NanOss Bioactive 3D, a synthetic three dimensional bioscaffold that supports bone formation and map3 Cellular Allogeneic Bone Graft, an implant that generates and maintains new bone are now available for commercial sale.
Consensus EPS and revenue estimates for 2014 and 2015 are $0.07/share on revenues of $237M and $0.13/share on revenues of $268M, respectively.
162 mutual funds have positions, down from 197 a year earlier.